Heimann David M, Weiner Louis M
Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
Surg Oncol Clin N Am. 2007 Oct;16(4):775-92, viii. doi: 10.1016/j.soc.2007.07.001.
Monoclonal antibodies have become increasingly used therapeutic agents for the treatment of solid cancer. Many are now being tested as components of adjuvant or first-line therapies to assess their efficacy in improving or prolonging survival. Selected unconjugated antibodies can exert clinically significant antitumor effects in many cancers. Antibody conjugates have been used to deliver toxic principles, such as radioactive particles, chemotherapeutic agents, and catalytic toxins, with increasing success in clinical trials.
单克隆抗体已越来越多地成为治疗实体癌的治疗药物。目前，许多单克隆抗体正在作为辅助治疗或一线治疗的组成部分进行测试，以评估其在改善或延长生存期方面的疗效。某些未偶联的抗体可在许多癌症中发挥具有临床意义的抗肿瘤作用。抗体偶联物已被用于递送毒性物质，如放射性粒子、化疗药物和催化毒素，在临床试验中取得了越来越大的成功。
